

Funded Study: Safety of B7H3 CAR T cells in Dogs with sarcoma.

Study Title: Evaluating the safety and immune activities of B7H3 targeting chimeric antigen receptor T cells in dogs with sarcoma.

Purpose of Study: The purpose of this study is to investigate the safety and activity of genetically modified immune cells (specifically chimeric antigen receptor T cells, CAR T cells for short) for specifically recognizing and eliminating tumor cells that express a specific surface protein called B7H3 when intravenously infused into pet dogs with sarcoma.

Inclusion Criteria:

- Dogs with a cytologic or histologic diagnosis of soft tissue sarcoma or osteosarcoma.
- The tumor must be surgically removable.
- Patient must be in good overall condition.

Exclusion Criteria:

- Patient has received prior chemotherapy or radiation treatment within 4 weeks of study enrollment.
- Patient is receiving immunosuppressive therapies.
- Patient has other serious illnesses.

Eligibility Diagnostics:

- Exam
- Cytology or histopathology consistent with soft tissue sarcoma or osteosarcoma

Procedures: Canine patients will receive an intravenous infusion of genetically modified, activated T cells (CAR T cells) followed by surgical removal of the tumor two days later. Tumor tissue will be collected for analysis to confirm successful CAR T cell infiltration into the tumor. During and/or following completion of CAR T cell therapy, blood may be collected for analysis.

Compensation: The study will partially defray costs. Blood collection, CAR T cell infusion are fully covered and up to \$2500 is provided towards the cost of surgery at the U of IL.

You will be responsible for any costs associated with the normal course of treatment and unrelated medical conditions.

Contact Information: Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.